Select Publications

 

  1. Hallaj S, Halfpenny W, Chuter BG, Weinreb RN, Baxter SL, Cui QN. Association between Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Exposure and Intraocular Pressure Change: GLP-1 Receptor Agonists and Intraocular Pressure Change. Am J Ophthalmol. 2024 Sep 3;. doi: 10.1016/j.ajo.2024.08.030. [Epub ahead of print] PubMed PMID: 39237049.

  2. Lawrence ECN, Guo M, Schwartz TD, Wu J, Lu J, Nikonov S, Sterling JK, Cui QN. Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma. Front Cell Neurosci. 2023 Jun 9;17:1156829. doi: 10.3389/fncel.2023.1156829. eCollection 2023.

  3. Guo M, Schwartz TD, Dunaief JL, Cui QN. Myeloid cells in retinal and brain degeneration. FEBS J. 2021 Sep 3. doi: 10.1111/febs.16177. FEBS J. 2022 Apr;289(8):2337-2361. doi: 10.1111/febs.16177. Epub 2021 Sep 15.

  4. Cui QN, Stein LM, Fortin SM, Hayes MR. The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma. Br J Pharmacol. 2022 Feb;179(4):715-726. doi: 10.1111/bph.15683.

  5. Sterling J, Hua P, Dunaief JL, Cui QN, VanderBeek BL. Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma. Br J Ophthalmol. 2021 Aug 19:bjophthalmol-2021-319232. doi: 10.1136/bjophthalmol-2021-319232. Online ahead of print. PMID: 34413054.

  6. Sterling JK, Adetunji M, Guttha S, Bargoud AR, Uyhazi KE, Ross AG, Dunaief JL, Cui QN. GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension. Cell Rep. 2020 Nov;33:108271. doi: 10.1016/j.celrep.2020.108271. PMID: 33147455.

  7. Cui QN, Bargoud AR, Ross AG, Song Y, Dunaief JL. Oral administration of the iron chelator deferiprone protects against loss of retinal ganglion cells in a mouse model of glaucoma. Exp Eye Res. 2020 Apr;193:107961. doi: 10.1016/j.exer.2020.107961. PMID: 32045598.

Complete List of Published Work